More Positive Data on Aducanumab in Alzheimer’s
If you have a few minutes, I hope you will read through this article on one of the more encouraging Alzheimer’s studies. Aducanumab made the news about the same time as we read of an ultrasound treatment now being studies.
The improvement using particular doses of this drug was impressive. So much so that they are now enrolling people in a much larger study. As they indicate in the article, their smaller study gave them a good basis for further testing, but a larger study is needed to see both the benefits and any changes that need to be made.
Other studies using a form of this drug did well early on, but weren’t able to sustain in the larger study.
Still, it is promising. They plan on reporting further later in the year.
Further analysis of phase 1b data show the monoclonal antibody appears to be effective regardless of APOE status and disease stage.